|
KMID : 0371319930450030343
|
|
Journal of the Korean Surgical Society
1993 Volume.45 No. 3 p.343 ~ p.352
|
|
|
The Expression of P-glycoprotein and the DNA Content as a Prognostic Indicator in Breast Cancers
|
|
Bae Sung-Han
|
|
|
Abstract
|
|
|
To evaluate the efficacy of P-glycoprotein and DNA content as prognostic indicators of breast cancer, thirty case of stage III breast cancer which were admitted and treated to Korea University Hospital between 1986 to 1987 were selected. Ten
cases
of
benign breast disease were also studied for control. Breast cancer patients were allocated into recurrent group(15 cases) and non recurrent group(15 cases) within 2 years after curative operations.
Immunohistochemical staining using murine monoclonal antibody C219 with labelled streptavidin method was used for P-glycoprotein. Eight out of 10 bening breast diseases showed focal distribution of P-glycoprotein expressions. There were 6 cases
of
1+, 6
cases of 2+, and 3 cases of 3+ P-glycoportoein expression in non-recurrnet group. there were 2 cases of 1+, 8 cases of 2+ and 5 cases of 3+ P-glycoprotein expressions in recurrent group. the expression of P-glycoprotien was higher in cancer than
in
benign lesion. However, there was no statistically significant difference between recurrent and nonrecurrent groups(P>0.05).
Paraffin embedded specimen were used for DNA content. All benign and non-recurrnet breast cancer specimens were diploid whereas 6 cases aneuploidy(40%) in recurrent group. Aneuploidy was more prevalent in patients who had more than 4 lymph nodes
metastasis. S-phase and S+G2M fractions were significantly higher in breast cancer than in benign diseases. But there was no difference between recurrent and non-recurrent groups.
As a result of this study, it is concluded that DNA ploidy is considered to be useful prognostic factors in assessing the recurrence and the proliferative fractions is not useful. The significant levels of P-glycoprotein expression were present I
breast
cancer before exposure to cytotoxic drugs associated with multidrug resistance. It is hoped that this immunohistochemical staining can be used to identify tumor with significant multidrug resistance expression os that multidr8ugn resistance
modulators
may be incorporated into the treatment of these tumors.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|